Evidence map›Paper›PMID 40075661›Full record

ReviewCancers2025

Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.

Jessica Chacon, Farah Faizuddin, Jack C McKee, Aadil Sheikh, Victor M Vasquez, Shrikanth S Gadad, Ghislaine Mayer, Sharon Siby, Molly McCabe, Subramanian Dhandayuthapani

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Microbiome Modulation for the Treatment of Solid Neoplasms.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Review
  4. Investigating the Impact ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica ChaconFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0000-0002-3657-7528
Farah FaizuddinFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Jack C McKeeFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Aadil SheikhFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0000-0001-6246-3439
Victor M VasquezFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0009-0003-7790-1296
Shrikanth S GadadFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0000-0003-0030-5472
Ghislaine MayerFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Sharon SibyFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0009-0008-1026-9923
Molly McCabeFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Subramanian DhandayuthapaniFoster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0009-0001-4390-3811

Funding

A Novel Hyper-Immunogenic Low Virulent BCG vaccine against TuberculosisR01AI175837 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI SUBRAMANIAN DHANDAYUTHAPANI · 2023 to 2026
$2.0M
A novel quadruple knockout MTb vaccine against tuberculosis (Supplement Resubmission)R15AI156647 · NIAID · TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER AT EL PASO · PI DHANDAYUTHAPANI, SUBRAMANIAN · 2021 to 2023
$626k
Analysis of Divergent Transcripts in Estrogen-Dependent SignalingR16GM149497 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Shrikanth Gadad · 2023 to 2026
$620k
NIAID NIH HHS R01 AI175837NIAID NIH HHS R15 AI156647NIGMS NIH HHS R16 GM149497
6 · The paper itself

Abstract

introductionThe emergence of cancer immunotherapy has revolutionized cancer treatment, offering remarkable outcomes for patients across various malignancies. However, the heterogeneous response to immunotherapy underscores the necessity of understanding additional factors influencing treatment efficacy. Among these factors, the human microbiota has garnered significant attention for its potential role in modulating immune response. Body: This review explores the intricate relationship between the human microbiota and cancer immunotherapy, highlighting recent advances and potential mechanisms underlying microbial influence on treatment outcomes.

conclusionInsights into the microbiome's impact on immunotherapy response not only deepen our understanding of cancer pathogenesis but also hold promise for personalized therapeutic strategies aimed at optimizing patient outcomes.

Indexed as

cancerimmunotherapymicrobiomemicrobiota

Identifiers

PMID40075661
PMCPMC11899421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.